ONC:NASDAQ
BeOne Medicines AG
$370.17
arrow_upward
+0.30%(+1.11) 1D
$372.14
arrow_upward
+0.53% (+1.97)bedtimeAfter hours
Closed: Oct 19, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ONC...
Open
$371.53
High
$376.34
Low
$368.51
Mkt. cap
45.32B
Avg. vol.
399.93K
Volume
289.75K
52-wk high
$385.22
52-wk low
$253.95
Beta
0.61
Shares outstanding
109.79M
No. of employees
12K
Open
$371.53
High
$376.34
Low
$368.51
Mkt. cap
45.32B
Avg. vol.
399.93K
Volume
289.75K
52-wk high
$385.22
52-wk low
$253.95
Beta
0.61
Shares outstanding
109.79M
No. of employees
12K
News stories
From web sources and news partners
Stocktwits
·
14 minutes ago
Dow, S&P 500, Nasdaq Edge Higher Amid Tech Rebound As Q3 Earnings Season Forges Ahead: DJT, AMZN, CBRS, CRWV Stocks In Focus
Yahoo Finance
·
34 minutes ago
Sam Stovall says history is key to what happens to the S&P 500 next year
Crypto Briefing
·
6 hours ago
AI stocks now make up 49% of the S&P 500, the second-highest concentration on record
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12K
FoundedOct 28, 2010
Headquarters-
SectorBiotechnology
Websitebeonemedicines.com